Former rep to argue First Amendment protection in court

Share this article:
A federal appeals court has agreed to hear oral arguments about whether the First Amendment protects a sales rep's ability to share information about off-label uses of a drug.
A date for oral arguments, which will be heard by the 2nd Circuit Court of Appeals (located in New York City), has not yet been set, according to Richard Samp, chief counsel at the Washington Legal Foundation (WLF). The WLF filed a brief with the court last April, and filed a motion in November to present oral arguments on behalf of the sales rep, which the court granted. Soon afterward, the Justice Department requested that the court allow Douglas Letter, a top DOJ appellate attorney, to also present oral arguments, Samp told MM&M. Letter did not immediately respond for comment.
The case stems from a sting operation in 2005 wherein Alfred Caronia, a sales rep for Orphan Medical, a wholly owned subsidiary of Jazz Pharmaceuticals, was asked by an internal medicine doctor (and government informer) to give a presentation on Xyrem. At the time, Xyrem was indicated only for cataplexy, and has since been approved for the treatment of narcolepsy, to reduce too much daytime sleepiness.
For the Xyrem presentation, Caronia and Peter Gleason, a physician whom Caronia had used in promotional efforts with physicians, met with the informer, and Gleason answered questions about off-label uses of Xyrem. After the meeting, both Caronia and Gleason were indicted on felony charges related to misbranding Xyrem, according to a report in the New York Law Journal.
Samp said the WLF believes that the First Amendment protects the right of individuals to speak truthfully about off-label uses. The government claims that it does not punish speech in off-label cases; it punishes conduct. “But then they point to speech,” said Samp.
The 2nd Circuit court initially said it would not hear oral arguments in the appeal, but the WLF brief made the court change its mind, according to Samp. Jazz plead guilty and paid $20 million in 2007 to settle criminal and civil investigations into illegal Xyrem marketing, and entered into a five year CIA.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Features

Is your marketing strategy stuck in 2005?

Is your marketing strategy stuck in 2005?

It is not enough to just have a killer black book or Rolodex. The market needs agile, swift marketing

Is guidance stifling social media?

Recent FDA draft guidance was meant to help companies create FDA-compliant tweets and handle third-party misinformation on the web. What other obstacles lie in the path of effective social media use?

FDA social media guides draw flak

FDA social media guides draw flak

Two FDA guidance documents on how health product manufacturers may participate in social media have drawn criticism from industry and consumer groups.